Umbilical cord blood (UCB) is recognized as an enriched source of endothelial progenitor cells (EPCs) with potential therapeutic value. Because cryopreservation is the only reliable method for long-term storage of UCB cells, the clinical application of EPCs depends on our ability to acquire them from cryopreserved samples; however, the feasibility of doing so remains unclear. In this study we demonstrate that EPCs can be isolated from cryopreserved UCB-derived mononuclear cells (MNCs). The number of outgrowth EPC colonies that emerged in culture from cryopreserved samples was similar to that obtained from fresh UCB. Furthermore, EPCs obtained from cryopreserved MNCs were phenotypically and functionally indistinguishable from freshly isolated ones, including the ability to form blood vessels in vivo. Our results eliminate the necessity of performing cell isolation procedures ahead of future clinical needs and suggest that EPCs derived from cryopreserved UCB may be suitable for EPC-related therapies.
INTRODUCTION
culture (5, 14) . However, the development of successful clinical therapies will likely depend on our ability to acquire functional EPCs from cryopreserved UCB. Here Umbilical cord blood (UCB) is an established source of hematopoietic stem cells (HSCs) used in the treat-we demonstrate for the first time that EPCs can be isolated and culture expanded from cryopreserved MNCs. ment of hematologic, oncologic, immunologic, and metabolic diseases (3, 4, (7) (8) (9) 11, 18, 19) . As a result, UCB is Moreover, EPCs from cryopreserved blood are phenotypically and mechanistically indistinguishable from now routinely collected, frozen, and stored in liquid nitrogen worldwide in anticipation of its future clinical their freshly isolated counterparts and retain their in vivo vasculogenic properties. These results suggest that EPCs use. In addition to HSCs, examination of UCB cellular components has uncovered other stem/progenitor cells obtained from banked UCB samples may be suitable for future clinical applications. with potential therapeutic value. For example, endothelial progenitor cells (EPCs), first identified in adult peripheral blood (1,12) but present in significantly higher MATERIALS AND METHODS numbers in UCB (10, 16, 17) , form vascular networks in Isolation of EPCs From Fresh and Cryopreserved vivo (2, 15, 20, 22) , a characteristic that has created moti-Cord Blood-Derived MNCs vation for developing new EPC-based vascularization therapies.
Human UCB samples (n = 3; 30 ml each) were obtained from cesarean sections and ex utero at the Brig-Although numerous laboratories already work with EPCs isolated from fresh mononuclear cells (MNCs), ham and Women's Hospital in accordance with an Institutional Review Board-approved protocol, which waived successful EPC isolation from cryopreserved UCB has not been reported. Current protocols follow early recom-the need for informed consent due to the samples being from discarded specimens. The complete MNC fraction mendations to plate freshly obtained MNCs as the most reliable method for obtaining outgrowth EPC colonies in was obtained (14, 16) and divided into three groups, 516 LIN ET AL.
which were used as follows: a) plated in culture (herein molecule assays, EPC monolayers were challenged with or without 10 ng/ml of tumor necrosis factor-α (TNF-referred to as fresh), b) cryopreserved (10% DMSO in FBS) and stored in liquid nitrogen for 1 month before α) for 5 h. Afterwards, the leukemia cell line HL-60 (2 × 10 6 cells) was added and incubated at 4°C on a rocking plating (referred to as cryo-1), and c) cryopreserved for 4 months before plating (cryo-4). Each of these groups platform for 45 min (6). Bound leukocytes were visualized and quantified using a phase contrast microscope contained the same amount of MNCs. All MNCs were seeded on 1% gelatin-coated plates using EPC medium and ImageJ analysis software. Additionally, leukocyte adhesion molecules were analyzed by flow cytometry (EGM-2 without hydrocortisone supplemented with 20% FBS and 1× glutamine-penicillin-streptomycin) using PE-conjugated antibodies against human E-selectin and ICAM-1 (6,16). Migration assays were carried with 15% autologous plasma (16) . Unbound cells were removed at 48 h. The number of endothelial-like colo-out in 8-µm trans-wells. Cells were added to the upper chamber and incubated in DMEM containing 2% FBS nies ( ≥ 50 cells) was counted under an inverted microscope at 2 weeks. At confluence, cells were purified us-with or without 50 ng/ml human VEGF-A (added to the lower chamber) for 16 h. The number of migrated cells ing CD31-coated beads as previously described (14, 16) . Purified EPCs are referred to as fresh-EPCs and cryo-was determined in triplicate by counting the cells present on the lower surface of the membrane after DAPI EPCs depending on whether they originated from fresh or cryopreserved MNCs, respectively. staining using a fluorescence microscope. Karyotyping was carried out from passage 8 cultures by G-banded Phenotypic Characterization of EPCs analysis at the Brigham and Women's cytogenetic core facility (Boston, MA). EPCs between passages 3 and 6 were characterized by standard flow cytometry (CD31, CD90, and CD45),
In Vivo Vasculogenic Properties of EPCs indirect immunostaining (CD31, vWF, and VE-Cadherin), and Western blot (CD31 and α-SMA) as previously Vasculogenesis was evaluated in vivo using our xenograft model as previously described (15) . Briefly, shown (15, 16) . For leukocyte adhesion and adhesion Figure 1 . Outgrowth EPC colonies from fresh and cryopreserved MNCs. Freshly isolated UCB-derived MNCs were divided into three groups: 1) noncryopreserved (fresh), 2) cryopreserved and stored in liquid nitrogen for 1 month (cryo-1), and 3) cryopreserved for 4 months (cryo-4). All MNCs were seeded on 1% gelatin-coated plates using EPC-medium. (A) Representative EC-like cell colonies obtained from fresh and cryo-1 MNCs at 2 weeks (white arrowheads mark colonies borders). Scale bar: 0.5 mm. (B) The number of colonies ( ≥ 50 cells) from each MNC group was counted at 2 weeks from three independent UCB samples (n = 3). p-Values were generated by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison tests. EPCs and bone marrow-derived mesenchymal progeni-3.5.9 software and a 4×/0.1 objective lens. Fluorescent images were taken with a Leica TCS SP2 Acousto-Opti-tor cells (MPCs) (2 × 10 6 total; 40:60 EPC/MPC ratio) were resuspended in 200 µl of Matrigel and subcutane-cal Beam Splitter confocal system equipped with a DMIRE2 inverted microscope using a 63×/1.4 oil objec-ously injected into 6-week-old male athymic nu/nu mice (n = 4). Implants were harvested at 7 days, and histolog-tive lens. Histology images were taken with a Primo Start Zeiss microscope equipped with an AxioCam ical (H&E) and immunohistochemical (human CD31) analyses were performed as previously shown (15) . Mi-MRc5 camera using a 40×/0.65 objective lens. crovessel density (vessels/mm 2 ) was reported as the average number of erythrocyte-filled microvessels in sec-Statistical Analysis tions from the middle of the implants (15) .
The data were expressed as means ± SEM. Unless Microscopy otherwise stated, all p-values reported were generated by individually comparing fresh-EPC and cryo-EPC groups Phase microscopy images were taken with a Nikon Eclipse TE300 inverted microscope using Spot Advance using two-tailed Student's unpaired t-tests. Additionally, multiple comparisons were performed where appropriate cytometry revealed that upregulation of E-selectin and ICAM-1 was the same in cryo-EPCs and fresh-EPCs by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison tests. Values of p < 0.05 (p = 0.4171 and p = 0.1417, respectively) ( Fig. 3A, B) . Also, this upregulation resulted in increased binding of were considered statistically significant.
HL-60 leukocytes (Fig. 3C ). Quantitative analysis of RESULTS leukocyte adhesion after TNF-α treatment showed no statistically significant differences between cryo-EPCs MNCs isolated from fresh UCB samples were cryopreserved by our group and stored for one (cryo-1) or and fresh-EPCs from the three independent cord blood preparations (p = 0.7775) (Fig. 3D) . Equivalent upregu-four (cryo-4) months in liquid nitrogen; in all cases, EPC colonies (identified by cobblestone morphology) lation of adhesion molecules (a functional property of ECs) in cryo-EPCs and fresh-EPCs suggests that cryo-emerged in culture with similar size, frequency, and time of appearance to those obtained from fresh UCB preservation does not impair physiological proinflammatory response in EPCs. MNCs (Fig. 1) . After quantification of all EPC colonies present at day 14, no statistically significant differences Finally, we evaluated the in vivo vasculogenic abilities of cryo-EPCs using our assay of human EPCs and were found between fresh, cryo-1, and cryo-4 groups of MNCs (p = 0.7548, one-way ANOVA) obtained from MPCs coimplanted into immune-deficient mice. As already reported with fresh-EPCs (15), histological exami-three independent UCB preparations ( Fig. 1B) . Additionally, we cryopreserved UCB-derived MNCs using an nation of cryo-EPC explants revealed extensive networks of microvessels filled with murine erythrocytes at alternative cryopreservation medium (90% autologous plasma, 10% DMSO, and 1% dextran-40) for 1 month day 7 (Fig. 4A ). These engineered microvessels stained positive for human CD31, confirming the structural par-in an effort to mimic clinical cryopreservation methods and found no statistical difference when compared to the ticipation of EPCs in blood vessel formation (Fig. 4A) , while murine capillaries were negative for human CD31 number of colonies obtained with FBS-based cryopreservation medium (data not shown). Next, EPCs from (black arrowheads). Quantification of average microvessel densities at day 7 revealed no statistically significant each group were purified by CD31 selection and characterized using standard assays. Indirect immunofluores-differences between implants prepared with cryo-EPCs and fresh-EPCs (p > 0.5, t-tests; n = 4 mice) ( Fig. 4B ). cent staining showed that cryo-EPCs expressed the endothelial (EC) markers CD31, VE-cadherin, and vWF When comparing all groups together from three independent UBC preparations, there were no statistically ( Fig. 2A) . While CD31 and VE-cadherin were localized at the cell-cell borders, vWF was expressed in a punctu-significant differences (p = 0.6077, one-way ANOVA). Carefully examination of vessels showed no histological ate pattern in the cytoplasm. Together, these were clear indications of an EC phenotype. Flow cytometry showed evidence of thrombosis (e.g., platelet aggregates and uniform fibrin deposit). This lack of thrombosis was true uniform expression of CD31 and absence of CD90 and CD45, confirming that neither cryo-EPCs nor fresh-for vessels engineered with both fresh-EPCs and cryo-EPCs, suggesting that both EPCs have the expected anti-EPCs were contaminated with mesenchymal or hematopoietic cells (Fig. 2B) . Western blot analysis confirmed thrombotic properties of endothelial cells in vivo. expression of CD31 and absence of α-SMA, a marker DISCUSSION of perivascular and mesenchymal cells (Fig. 2C) . In addition, both cryo-EPCs and fresh-EPCs were equally re-
The discovery of EPCs in peripheral blood created an exciting opportunity to noninvasively obtain large quan-sponsive to VEGF as shown by migration assay (p = 0.4802) (Fig. 2D ). Finally, cells cultured for eight pas-tities of autologous ECs for either therapeutic vascularization or tissue engineering. However, the process of sages were karyotypically stable ( Fig. 2E depicts representative sorted karyograms of cryo-EPCs showing a obtaining blood-derived EPCs with bona fide blood vessel-forming ability has not been straightforward due to normal male karyotype of 46,XY), suggesting that acquisition of EPCs from cryopreserved MNCs does not the low concentration of circulating EPCs relative to leukocytes and the lack of a unique set of distinctive increase the risk of chromosomal abnormalities.
We also evaluated functional properties of cryo-EPC markers. For these reasons, the isolation of circulating EPCs by flow cytometry or other immunological EPCs. First, we tested whether cryo-EPCs upregulated leukocyte adhesion molecules in response to the inflam-techniques is still a challenging problem. As a result, the most successful way to isolate EPCs is based on meth-matory cytokine TNF-α. As expected, E-selectin was low to undetectable and ICAM-1 was low (though de-ods similar to those originally reported for endothelial outgrowth colonies from peripheral blood (12). First, tectable) in the untreated cryo-EPCs. Both adhesion molecules were markedly upregulated after 5 h of incu-MNCs are collected from fresh blood and plated onto collagen-coated plates in endothelial-specific growth bation with TNF-α (Fig. 3A) . Quantification by flow In vivo vasculogenic ability of EPCs isolated from cryopreserved MNCs. In vivo vasculogenic properties were evaluated by subcutaneous coimplantation of MPCs with either fresh-EPCs or cryo-EPCs into 6-week-old nude mice. Both fresh-EPCs and cryo-EPCs were acquired from three independent UCB samples (cb1-cb3). (A) Macroscopic views of explants at day 7 are depicted in insets. Scale bar: 5 mm. H&E staining at day 7 (top panels) revealed the presence of numerous blood vessels containing murine erythrocytes (yellow arrowheads). Immunohistochemistry (bottom panels) showed that engineered microvessels stained positive for human CD31 (yellow arrowheads), while murine capillaries (black arrowheads) did not. All images are representative of implants harvested from four different mice (yellow arrowheads indicate blood vessels) Scale bar: 50 µm. (B) Microvessel densities of implants harvested at day 7 were quantified by counting lumenal structures containing erythrocytes. For each UCB sample evaluated (cb1-cb3), bars represent the mean microvessel density determined from four replicate implants (one mouse each) ± SEM. p-Values were generated by individually comparing fresh-EPC and cryo-EPC groups using two-tailed Student's unpaired t-tests. media (10,12,22), and then, EC-like colonies emerge expensive cell isolation procedures ahead of potential clinical needs and reduces the dependency on freshly from the adherent cell population after 1-3 weeks in culture (16, 22) . Despite the success of this procedure, collected UCB, which is especially convenient for laboratories not located near clinical facilities. the methodology is limited by the requirement of freshly collected blood. for the first time the feasibility of obtaining EPCs from REFERENCES cryopreserved UCB MNCs. Following the methodology described above, we obtained similar numbers of EPC
